These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6479022)

  • 21. Clinical evaluation of moxalactam therapy.
    Venezio FR; Westenfelder GO; Cook FV; Williams JE; Carruthers M; Reisberg BE; Emmerman J; Phair JP
    J Antimicrob Chemother; 1982 Nov; 10(5):435-43. PubMed ID: 6217184
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.
    Mueller O; Fabricius K; Krueger E; Rueckert U
    Rev Infect Dis; 1982; 4 Suppl():S688-91. PubMed ID: 6218584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moxalactam treatment of serious infections primarily due to Haemophilus influenzae type b in children.
    Kaplan SL; Mason EO; Kvernland SJ; Loiselle EM; Feigin RD
    Pediatrics; 1983 Feb; 71(2):187-91. PubMed ID: 6218472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections.
    Siebert WT; Kopp PE
    Am J Med; 1985 Nov; 79(5B):141-5. PubMed ID: 4073082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of latamoxef in the treatment of infections of newborn infants].
    Kobayashi Y; Haruta T; Kuroki S; Okura K
    Jpn J Antibiot; 1983 Sep; 36(9):2359-63. PubMed ID: 6655854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxalactam: clinical summary of efficacy and safety.
    Kammer RB
    Rev Infect Dis; 1982; 4 Suppl():S712-9. PubMed ID: 6218589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Moxalactam in pediatrics. Clinical and pharmacokinetic experience. Apropos of 37 cases].
    Bégué P; Safran C; Fleurette J; Brun Y; Floret D; Monnet P
    Sem Hop; 1983 Jun; 59(26):1972-6. PubMed ID: 6310789
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of serious infections with moxalactam.
    Ribner BS; Raeder R; Becker TM; Freimer EH
    Am J Med; 1983 Mar; 74(3):396-400. PubMed ID: 6219576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections.
    Busuttil RW; McGrattan MA; Winston DJ
    Rev Infect Dis; 1982; 4 Suppl():S676-82. PubMed ID: 6218582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticarcillin plus clavulanic acid versus moxalactam in the treatment of skin and soft tissue infections.
    Rao B; See RC; Chuah SK; Bansal MB; Lou MA; Thadepalli H
    Am J Med; 1985 Nov; 79(5B):126-9. PubMed ID: 4073078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cephalosporin therapy in intraabdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin.
    Wilson SE
    J Chemother; 1989 Jul; 1(4 Suppl):820-2. PubMed ID: 16312655
    [No Abstract]   [Full Text] [Related]  

  • 33. Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections.
    Sweet RL; Gall SA; Gibbs RS; Hemsell DL; Knuppel RA; Lane TW; Miller RD; Newton ER; Poindexter AN; Reguero W
    Am J Surg; 1988 May; 155(5A):56-60. PubMed ID: 3287970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developmental pharmacokinetics of moxalactam.
    Reed MD; Aronoff SC; Myers CM; Husak MP; Bertino JS; Blumer JL
    Antimicrob Agents Chemother; 1983 Sep; 24(3):383-7. PubMed ID: 6638995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.
    Eng RH; Cherubin C; Smith SM; Buccini F
    Antimicrob Agents Chemother; 1984 Dec; 26(6):850-6. PubMed ID: 6395799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Penetration of moxalactam into the cerebrospinal fluid and its application in therapy of bacterial meningitis.
    Cheng DL; Shi FW; Liu YC; Liu CY
    Taiwan Yi Xue Hui Za Zhi; 1987 Jun; 86(6):634-8. PubMed ID: 3655708
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and pharmacokinetic evaluation of moxalactam in infants and children.
    Varghese M; Khan AJ; Quaye G; Patel U; Kumar K; Evans HE
    Chemotherapy; 1982; 28(6):417-20. PubMed ID: 6218971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
    Drusano GL; Ryan PA; Standiford HC; Moody MR; Schimpff SC
    Rev Infect Dis; 1984; 6(3):357-63. PubMed ID: 6330835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.